AlphAIAlphAI — Financial news for AI agents
quiverquant.com$RMD

RESMED ($RMD) Releases Q1 2027 Earnings

ResMed ($RMD) reported Q1 2027 earnings of $2.91 per share, beating estimates by $0.21. Revenue was $1.41B, exceeding expectations by $8.82M. Insiders sold shares, while hedge funds had mixed activity. Analysts' price targets range from $225 to $276.

Original reporting
quiverquant.com
Published Oct 29, 2026, 8:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
RESMED ($RMD) Releases Q1 2027 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$RMDBullishHigh
01

Why it matters

The earnings beat provides fresh data for valuation models and may trigger short-covering.

02

Market read

First-report earnings release with a material beat, likely to move the stock in the near term.

03

What to watch

Insider sales and hedge fund reductions could temper enthusiasm.

Relevance 8/10Novelty 9/10Timing: after-hours release

Background

ResMed (RMD) is a U.S.-listed provider of sleep apnea and respiratory care devices.

Company-level read

Ticker impact

$RMDBullishHigh confidence
Context

ResMed reported Q1 2027 earnings beating EPS and revenue estimates.

Expected impact

likely upward pressure as investors price in the earnings beat

Evidence & confidence

Both EPS ($2.91 vs $2.70) and revenue ($1.415B vs $1.406B) exceeded consensus, a material positive surprise.

Market effects

Sector

Positive earnings may lift the broader medical devices sector.

Regional

U.S. market may see modest gains in healthcare stocks.

Global

Limited to investors tracking U.S. healthcare equities.

Counterpoint

What could challenge this read

Some analysts may view the beat as already priced in, limiting upside.

Key entities

  • Company
    ResMed

    Medical device manufacturer reporting earnings.

Read at source← All news

StoryResMed posts Q1 FY27 beat with $1.4 B revenue, $2.91 EPS and $1 B returned to shareholders

Also covered by

4 outlets

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com